SNDX - Syndax Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07
2023-11-02 16:45:43 ET
More on Syndax Pharmaceuticals
- Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
- Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
- Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript
- BofA starts Syndax at buy, cites "first mover advantage" for leukemia drug
- Syndax initiated Buy at Goldman Sachs citing sales ops next year
For further details see:
Syndax Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07